Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
de Pablos-Aragoneses, A.
Trejo, J. L.
Sepúlveda, J. M.
Moreno, L. M.
Mazarico Gallego, J.
Garrido-Martín, E. M.
Cohen-Jonathan Moyal, E.
Young, L. S.
Grivennikov, S. I.
Faria, C. C.
Lee, Rebecca J
Lorigan, Paul C
Le Rhun, E.
Martin, S. M.
MetadataShow full item record
AbstractWhole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understanding of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models of brain metastasis resistant to WBRT, we identified activation of the S100A9–RAGE–NF-κB–JunB pathway in brain metastases as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary melanoma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively, we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer that balances therapeutic benefit and toxicity.
CitationMonteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, et al. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nat Med. 2022;28(4):752-65.
- Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases.
- Authors: Jiang C, Kleber TJ, Switchenko JM, Khan MK
- Issue date: 2021 Feb 8
- Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.
- Authors: Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, Vardy JL, Nowak AK, Dhillon HM, Ahmed T, Shivalingam B, Long GV, Menzies AM, Hruby G, Drummond KJ, Mandel C, Middleton MR, Reisse CH, Paton EJ, Steel V, Williams NC, Scolyer RA, Morton RL, Thompson JF
- Issue date: 2019 Nov 20
- The treatment of brain metastases from malignant melanoma.
- Authors: Douglas JG, Margolin K
- Issue date: 2002 Oct
- Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
- Authors: Frakes JM, Figura NB, Ahmed KA, Juan TH, Patel N, Latifi K, Sarangkasiri S, Strom TJ, Chinnaiyan P, Rao NG, Etame AB
- Issue date: 2015 Nov
- Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
- Authors: Chia BSH, Leong JY, Ong ALK, Lim C, Poon SH, Chua MLK, Chua KLM, Kusumawidjaja G, Chua ET, Wong FY, Lee TS
- Issue date: 2020 Oct 30